ME (23andMe Inc.) Indikator likuiditas cepet

23andMe Holding Co. (ME) generates revenue through the sale of DNA kits and paid digital health monitoring services. This price action chart below demonstrates the metric at 0.84. The business is implementing "green" standards in test production and strictly stores information within the US to mitigate geopolitical risks and comply with stringent genetic data privacy regulations.

The quick ratio measures a company's ability to meet short-term obligations without relying on the sale of inventory. By analyzing quick liquidity, an investor assesses a business's margin of safety through the ratio of cash and accounts receivable to total debt. This metric reveals actual solvency by excluding illiquid assets. For 23andMe Holding Co. (ME), this confirms financial stability while leveraging the largest genetic database in partnership with pharmaceutical behemoths.